Multivariate analyses for overall survival and event-free survival from time of randomization
| . | OS . | EFS . | ||
|---|---|---|---|---|
| Variable . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Treatment arm—GDP | 1.05 (0.82-1.34) | .67 | 1.02 (0.82-1.27) | .84 |
| Histology—TRIL | 0.92 (0.66-1.27) | .61 | 0.83 (0.62-1.13) | .23 |
| Duration of CR/PR <1 y vs SD/PD for previous therapy | 0.68 (0.52-0.88) | .004 | 0.68 (0.53-0.87) | .002 |
| Duration of CR/PR >1 y vs SD/PD for previous therapy | 0.24 (0.16-0.37) | <.0001 | 0.31 (0.22-0.44) | <.0001 |
| Age >60 y | 1.15 (0.88-1.50) | .30 | 1.14 (0.90-1.44) | .27 |
| BM involved | 0.99 (0.61-1.63) | .99 | 1.13 (0.74-1.75) | .57 |
| ECOG PS 0-1 | 0.98 (0.69-1.38) | .89 | 1.08 (0.78-1.49) | .66 |
| Stage I-II | 0.95 (0.71-1.27) | .72 | 0.84 (0.65-1.09 | .19 |
| Prior radiation | 1.31 (0.98-1.76) | .07 | 1.25 (0.95-1.64) | .11 |
| Prior rituximab | 1.59 (1.14-2.24) | .007 | 1.66 (1.24-2.22) | .0007 |
| Normal LDH | 0.40 (0.31-0.53) | <.0001 | 0.52 (0.41-0.66) | <.0001 |
| Presence of B symptoms | 1.47 (1.14-1.89) | .003 | 1.32 (1.05-1.66) | .02 |
| Extranodal sites 0-1 | 0.65 (0.49-0.87) | .003 | 0.79 (0.61-1.02) | .08 |
| . | OS . | EFS . | ||
|---|---|---|---|---|
| Variable . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| Treatment arm—GDP | 1.05 (0.82-1.34) | .67 | 1.02 (0.82-1.27) | .84 |
| Histology—TRIL | 0.92 (0.66-1.27) | .61 | 0.83 (0.62-1.13) | .23 |
| Duration of CR/PR <1 y vs SD/PD for previous therapy | 0.68 (0.52-0.88) | .004 | 0.68 (0.53-0.87) | .002 |
| Duration of CR/PR >1 y vs SD/PD for previous therapy | 0.24 (0.16-0.37) | <.0001 | 0.31 (0.22-0.44) | <.0001 |
| Age >60 y | 1.15 (0.88-1.50) | .30 | 1.14 (0.90-1.44) | .27 |
| BM involved | 0.99 (0.61-1.63) | .99 | 1.13 (0.74-1.75) | .57 |
| ECOG PS 0-1 | 0.98 (0.69-1.38) | .89 | 1.08 (0.78-1.49) | .66 |
| Stage I-II | 0.95 (0.71-1.27) | .72 | 0.84 (0.65-1.09 | .19 |
| Prior radiation | 1.31 (0.98-1.76) | .07 | 1.25 (0.95-1.64) | .11 |
| Prior rituximab | 1.59 (1.14-2.24) | .007 | 1.66 (1.24-2.22) | .0007 |
| Normal LDH | 0.40 (0.31-0.53) | <.0001 | 0.52 (0.41-0.66) | <.0001 |
| Presence of B symptoms | 1.47 (1.14-1.89) | .003 | 1.32 (1.05-1.66) | .02 |
| Extranodal sites 0-1 | 0.65 (0.49-0.87) | .003 | 0.79 (0.61-1.02) | .08 |